It is a pharma private limited company based in Mumbai, Maharashtra, India, established in 2011.
2011 | Mumbai, Maharashtra, India | ActiveImmunocon Bioremedies Private Limited, a active private limited company, was established on 07 September 2011 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the pharma sector, it holds CIN: U24233MH2011PTC221624. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹0.10 M and a paid-up capital of ₹0.10 M.
It upholds a compliant status. Its leadership includes Shakti Nath Upadhyay (Director), Pooja Mehul Parekh (Director), Sonali Mehul Parekh (Director). Past directors included Mehul Parekh Jayant. Its latest AGM occurred on 30 September 2022, with the balance sheet filed on 31 March 2022. It is based at E/501, Sky Park Chs Ltd, Oshiwara Garden Road, Next To Hdfc House, Off. S.V.Road, Goreg, Aon - West, Mumbai, Maharashtra, 400104.
U24233MH2011PTC221624
221624
07 September 2011
₹0.10 M
₹0.10 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Immunocon Bioremedies Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shakti Nath Upadhyay | Director | 07 Sep 2011 | Current |
| Pooja Mehul Parekh | Director | 23 Sep 2013 | Current |
| Sonali Mehul Parekh | Director | 23 Sep 2013 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 25 Nov 2013 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Immunocon Bioremedies Private Limited, for the financial year ended 2016, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
In 2017, Immunocon Bioremedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Immunocon Bioremedies has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Immunocon Bioremedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immunocon Bioremedies's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Immunocon Bioremedies Private Limited last Annual general meeting of members was held on 30 Sep 2022 as per latest MCA records. was documented.
Immunocon Bioremedies Private Limited has filed its annual Financial statements for the year ended 31 Mar 2022 with Roc Mumbai. was recorded as a recent event.
The activity Pooja Mehul Parekh was appointed as a Director was appointed as a Director on 23 Sep 2013 & has been associated with this company since 12 years 2 months . was completed.
Progress on Sonali Mehul Parekh was appointed as a Director was appointed as a Director on 23 Sep 2013 & has been associated with this company since 12 years 2 months . was documented.
Shakti Nath Upadhyay was appointed as a Director was appointed as a Director on 07 Sep 2011 & has been associated with this company since 14 years 2 months . was recorded as a recent event.
The activity Immunocon Bioremedies Private Limited was registered on 07 Sep 2011 with Roc Mumbai & aged 14 years 2 months as per MCA records. was completed.
The CIN of Immunocon Bioremedies Private Limited is U24233MH2011PTC221624.
Immunocon Bioremedies Private Limited is headquartered at E/501, Sky Park Chs Ltd, Oshiwara Garden Road, Next To Hdfc House, Off. S.V.Road, Goreg, Aon - West, Mumbai, Maharashtra, 400104.
Immunocon Bioremedies Private Limited was incorporated on 07 September 2011.
The current directors of Immunocon Bioremedies Private Limited are
The primary industry of Immunocon Bioremedies Private Limited is Pharma.
Immunocon Bioremedies Private Limited is unlisted.
The authorized capital of Immunocon Bioremedies Private Limited is ₹0.10 M, and the paid-up capital is ₹0.10 M.
The compliance status of Immunocon Bioremedies Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX